Brief: Adverum Biotechnologies Introduces An Intravitreal Gene Therapy Program For Geographic Atrophy And Presents Data On Its Ocular Gene Therapy Platform
18/05/2023 14:11
Adverum Biotechnologies Inc ADVM.O :
* ADVERUM BIOTECHNOLOGIES INTRODUCES AN INTRAVITREAL GENE
THERAPY
PROGRAM FOR GEOGRAPHIC ATROPHY AND PRESENTS DATA ON ITS OCULAR
GENE THERAPY PLATFORM
Source text for Eikon: ID:nGNXB39P3
Further company coverage: ADVM.O
Recent news on Adverum Biotechnologies
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Adverum Reminds Stockholders To Tender Their Shares Into The Offer By Lilly
Brief: Adverum Biotechnologies Inc - Are-Nc Region No. 21 Llc Terminates Certain Lease Agreement With Adverum Biotechnologies - SEC Filing
Eli Lilly bets on eye care with buyout of gene therapy developer Adverum (updated)